Pfizer $650M Manufacturing Center Planned in Groton, CT

Pfizer (PFE) plans to invest $650 million in a new center for global clinical trials in Connecticut. The facility aims to enhance the company's research and development capabilities. According to the company, this investment is part of its long-term strategy to advance clinical trials and potentially improve its pipeline of new treatments.

Edison Scientific's AI scientist, Kosmos, will work on Pfizer's drug-development data in oncology, immunology, and other areas. The AI platform aims to improve R&D efficiency by integrating public and proprietary data. Edison claims Kosmos can reduce IND preparation time by 75% and recover $99M in peak sales per program, according to a case study.

Freedom Broker raised Pfizer's (PFE) price target to $34, citing strong Q3 2026 results with revenue of $16.6B and EPS of $0.87, both exceeding estimates. The company also raised its full-year guidance. Argus also raised its target to $40. PFE shares are up 26% YTD and offer a 5.76% dividend yield.

Pfizer plans a $650 million investment in a 220,000-square-foot facility in Groton, operational by 2031. The center will support clinical trials and consolidate employees. The Groton campus is a key R&D hub for Pfizer, according to the company.

Pfizer Korea's Litfulo (ritlecitinib tosylate) cleared a reimbursement review for severe alopecia areata in adults and adolescents aged 12+ by the Health Insurance Review and Assessment Service. The decision may improve treatment access, but coverage depends on further steps, including price negotiations. Litfulo is a once-daily oral treatment that promotes hair regrowth by blocking inflammatory signals.

Pfizer plans to invest $650 million in a new Manufacturing Technology Center in Groton, Connecticut. The 220,000-square-foot facility will support clinical drug production, with construction starting in Q2 2027 and operations beginning in mid-2031. Local officials highlight the long-term commitment to the region and job creation.